For cancer research it is important to consider the longer term. It is often many years before a conclusion about the merit of a new procedure can be reached.
This study looked at the long-term benefits of hyperthermic intraperitoneal chemo (HIPEC) by revisiting the subjects of the OVHIPEC-1 trial 7 years after the trial ceased. The initial trial showed improved progression free survival and overall survival for those women who received HIPEC as part of their therapy in addition to normal chemo for ovarian cancer.
Review of the data has enabled the determination of 10-year survival for the first time, which shows that HIPEC benefit is prolonged. More patients survive with better quality of life due to longer intervals between recurrence and less platinum resistance making repeat treatment easier.
No comments:
Post a Comment